SARASOTA, Fla., April 4,
2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:
INVO), a commercial-stage fertility company focused on expanding
access to advanced treatment worldwide with its INVOcell® medical
device and the intravaginal culture ("IVC") procedure it enables,
announced today that it will be participating in the Lytham
Partners Spring 2022 Investor Conference taking place virtually on
April 4-7, 2022.
The Company's webcast presentation will be available for viewing
at 11:00am ET on Monday, April 4,
2022, on the Company's website or at
https://wsw.com/webcast/lytham4/invo/2054868. The webcast will also
be archived and available for replay.
Management will be participating in virtual one-on-one meetings
throughout the event. To arrange a meeting with management, please
contact Lytham Partners at 1x1@lythampartners.com or register
at www.lythampartners.com/spring2022invreg.
About INVO Bioscience
We are a commercial-stage fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our flagship product is INVOcell®, a revolutionary
medical device that allows fertilization and early embryo
development to take place in vivo within the woman's body.
Our primary mission is to implement new medical technologies aimed
at increasing the availability of affordable, high-quality,
patient-centered fertility care. This treatment solution is the
world's first intravaginal culture technique for the incubation of
oocytes and sperm during fertilization and early embryo
development. This technique, designated as "IVC", provides patients
a more natural, intimate, and more affordable experience in
comparison to other ART treatments. The IVC procedure can deliver
comparable results at a fraction of the cost of traditional in
vitro fertilization ("IVF") and is a significantly more effective
treatment than intrauterine insemination ("IUI"). Our
commercialization strategy is focused on the opening of dedicated
"INVO Centers" offering the INVOcell® and IVC procedure (with three
centers in North America now
operational), in addition to continuing to sell our technology
solution into existing fertility clinics. For more information,
please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov . We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-participate-in-the-lytham-partners-spring-2022-investor-conference-301516403.html
SOURCE INVO Bioscience, Inc.